You are here: Industry Insights > Codagenix

News List

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies prnewswire
September 28, 2021
Codagenix Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced that their novel intranasal COVI-VAC vaccine...
First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate europeanpharmaceuticalreview
January 14, 2021
The trial will assess the safety and immunogenicity of a single intranasal dose of COVI-VAC in 48 healthy volunteers in the UK.
Codagenix, Serum Institute of India Announce Trial Single Dose Vaccine for COVID-19 americanpharmaceuticalreview
January 05, 2021
Codagenix and the Serum Institute of India (SIIPL) announced a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK.
Codagenix Completes Dosing for Trial of Live-Attenuated, Intranasal Vaccine for RSV americanpharmaceuticalreview
December 18, 2020
Codagenix announced the completion of dosing in a Phase 1 clinical trial of its live attenuated CodaVax™-RSV vaccine, an intranasally-administered vaccine for the prevention of respiratory syncytial virus (RSV).
Green light for UK trial of nasal coronavirus vaccine pharmatimes
December 16, 2020
Open Orphan and Codagenix have received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase I study of its COVID-19 vaccine.
Serum Institute of India: outsourced manufacturing of COVID-19 vaccines europeanpharmaceuticalreview
September 27, 2020
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
Serum Institute starts manufacturing Codagenix’s COVID-19 vaccine candidate expresspharma
September 23, 2020
CDX-005, an intranasal, live-attenuated vaccine candidate, has completed preclinical animal studies, and Codagenix expects to initiate human trials by end of 2020.
Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19 PRNewswire
February 14, 2020
There are no licensed vaccines or therapeutics for this novel coronavirus, now referred to as COVID-19.
RSV vaccine player Codagenix snags $3M in public and private investment fiercepharma
October 13, 2017
Add a new contender to the list of companies aspiring to develop an effective respiratory syncytial virus (RSV) vaccine and nab a share of a potential multibillion-dollar market: Codagenix.